ADCT 8-K SEC Filing Analysis

Latest settled — T+20d

ADCT ▼ -7.61% at T+20d

NEUTRAL call ✗ call lost -7.61% · α vs SPY -13.25% · entry $3.68 → $3.40

Next anchor: T+60d in 6w

Last close $1.05 (close Jun 12) · -71.47% from $3.68 entry

Entry anchored
May 1, 03:59 PM ET
via Databento tick

T+1d

+2.17%

call +2.17% · α +1.38%

$3.76

settled 6w ago

T+5d

-5.43%

call -5.43% · α -8.37%

$3.48

settled 5w ago

T+20d

-7.61%

call -7.61% · α -13.25%

$3.40

settled 13d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

ADC Therapeutics reported Q1 2026 product revenue of $20.0M (+15% YoY), in line with consensus, but GAAP net loss per share of ($0.21) slightly missed the ($0.20) consensus. The company reiterated its expected cash runway into 2028 and highlighted pending LOTIS-5 topline data in Q2 2026 as the primary near-term catalyst.

Actionable Insight

The earnings report itself is unlikely to move the stock materially. Focus shifts entirely to the imminent LOTIS-5 topline data, which is the key binary catalyst. Traders should watch for press release timing and prepare for volatility based on trial outcomes.

Key Facts

Q1 2026 net product revenue: $20.0M, up from $17.4M in Q1 2025
GAAP net loss $(0.21) per share vs consensus $(0.20) (small miss)
Adjusted net loss $(0.13) per share improved from $(0.22) a year ago
Cash and cash equivalents: $231.0M as of March 31, 2026
LOTIS-5 Phase 3 topline data expected in Q2 2026 (any day)
No financial guidance provided

Financial Impact

Q1 revenue in line, EPS miss of ~5% but adjusted loss improved; limited financial impact given pre-profit stage.

revenueepscash

Risk Factors

LOTIS-5 trial failure would significantly impair the stock
Dilution risk from potential future financing needs
Competitive pressure from other DLBCL therapies

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

92% bullish (12 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001628280-26-029524
Document: adc-20260504.htm	0001628280-26-029524
Document: 0001628280-26-029524-index-headers.html	0001628280-26-029524
Document: 0001628280-26-029524-index.html	0001628280-26-029524
Document: 0001628280-26-029524.txt	0001628280-26-029524
8-K Data (Synthetic)	0001628280-26-029524

5 reports for ADCT

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ADCT — sortable, filterable
	Type				Now
Jun 3, 2026 11d ago	8-K MIXED ★ 6/10	$1.32 $1.03	▼ −21.97%	▼ −19.40%	$1.05 (−20.45%)
May 4, 2026 5w ago	8-K NEUTRAL ★ 4/10	$3.68 $3.76	▲ +2.17%	▲ +1.38%	$1.05 (−71.47%)
Apr 20, 2026 7w ago	DEFA14A NEUTRAL ★ 2/10	$4.25 $4.11	▼ −3.29%	▼ −2.64%	$1.05 (−75.29%)
Mar 17, 2026 12w ago	EFFECT NEUTRAL ★ 4/10	$4.11 $4.01	▼ −2.43%	▼ −1.03%	$1.05 (−74.45%)
Mar 10, 2026 13w ago	S-3 BEARISH ★ 6/10	$4.88 $4.35	▲ +10.86%	▲ +9.38%	$1.05 (+78.48%)

US Market Status

Market Closed — Opens in 4h 20m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access